CMD Consulting
Small consulting firm providing epidemiology, biostatistics, health economics and outcomes research, and scientific writing to support development, regulatory submissions, and market access for biotechnology and pharmaceutical products.
Industries
Nr. of Employees
small (1-50)
Services
Estimate disease incidence/prevalence; design observational, qualitative, and RWE studies; develop conceptual disease models and PCOA strategies.
Develop population and economic models, budget-impact and cost-utility analyses, and provide parameter estimates for modeling.
Prepare patient-centered outcome evidence dossiers, AMCP dossiers, manuscripts for peer-reviewed journals, abstracts, and internal study reports.
Support design and implementation of post-market studies, safety surveillance, and patient registries.
Estimate disease incidence/prevalence; design observational, qualitative, and RWE studies; develop conceptual disease models and PCOA strategies.
Develop population and economic models, budget-impact and cost-utility analyses, and provide parameter estimates for modeling.
Prepare patient-centered outcome evidence dossiers, AMCP dossiers, manuscripts for peer-reviewed journals, abstracts, and internal study reports.
Support design and implementation of post-market studies, safety surveillance, and patient registries.
Expertise Areas
- Epidemiology
- Health economics and outcomes research (HEOR)
- Patient-reported outcomes and psychometrics
- Real-world evidence and observational studies
Key Technologies
- Real-world evidence (RWE) study methods
- Epidemiologic methods for incidence/prevalence estimation
- Patient-reported outcome (PRO) instrument development and psychometric analysis
- Population-effectiveness and decision-analytic modeling
News & Updates
Health status analysis of a randomized, double-blind, placebo-controlled, phase 3 trial in obstructive hypertrophic cardiomyopathy.
Population-effectiveness modeling to estimate residual disease burden after neoadjuvant therapy in high-risk HER2+ early-stage breast cancer.
Analysis of echocardiographic parameters and health status in obstructive hypertrophic cardiomyopathy.
Health status analysis of a randomized, double-blind, placebo-controlled, phase 3 trial in obstructive hypertrophic cardiomyopathy.
Population-effectiveness modeling to estimate residual disease burden after neoadjuvant therapy in high-risk HER2+ early-stage breast cancer.
Analysis of echocardiographic parameters and health status in obstructive hypertrophic cardiomyopathy.